IMPROVEMENT OF THERAPY FOR PATIENTS WITH LOCALIZED SCLERODERMA

Authors:

Abstract:

Localized scleroderma is a chronic multifactorial autoimmune disease affecting the skin and subcutaneous tissue. The aim of this study was to compare the clinical efficacy of two complex treatment regimens in patients with localized scleroderma combined with Lyme borreliosis. The study compared two regimens: one based on benzylpenicillin and the other on doxycycline hydrochloride 100 mg twice daily in 45 patients aged 20 to 64 years. Clinical manifestations, lesion activity using the modified Localized Scleroderma Skin Severity Index, and serum levels of pro-inflammatory interleukin-6 and anti-inflammatory interleukin-10 were evaluated before and 30 days after treatment. The results demonstrated a significantly greater reduction in skin lesion activity and pro-inflammatory interleukin-6 levels, alongside an increase in anti-inflammatory interleukin-10 in the doxycycline-treated group compared to benzylpenicillin. These results suggest that doxycycline hydrochloride offers superior clinical and immunological benefits in patients with localized scleroderma associated with Lyme borreliosis.

Keywords:

localized scleroderma Lyme-borreliosis cytokines benzylpenicillin doxycycline hydrochloride

References:

1. Filimonkova NN, Temirbulatova AR, Kuznetsov ID. Modern data on localized scleroderma and methods of its therapy. Pharmateca. 2022;29(13):49–52. doi: 10.18565/pharmateca.2022.13.49-52.
2. Dirr M, Bitterman A, Al Dehneem R, Gottlieb AB. Successful Treatment of Morphea with Topical Ruxolitinib. SKIN: The Journal of Cutaneous Medicine. 2023;7(2):747–749. DOI: 10.25251/skin.7.2.19.
3. Hernandez A, Zapata LL, Mutka M, Torok KS, Ledbetter L, Zigler CK. Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review. Pediatric Rheumatology. 2024;22:77. doi: 10.1186/s12969-024-01014-x.
4. Li X, Huang C, Chen Z. Global research status of localised scleroderma reported over the period 1993–2022: A 30-year bibliometric analysis. International Wound Journal. 2024; Volume & issue. doi: 10.1111/iwj.14559.
5. Knobler R, Geroldinger-Simić M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, et al. Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology. 2024;38(7):1251–1280. doi: 10.1111/jdv.19912.
6. Kreuter A, Moinzadeh P, Kinberger M, Horneff G, Worm M, Werner RN, et al. S2k guideline: Diagnosis and therapy of localized scleroderma. JDDG (Journal der Deutschen Dermatologischen Gesellschaft). 2024;22(4):605–620. doi: 10.1111/ddg.15328.
7. Papara C, De Luca DA, Bieber K, Vorobyev A, Ludwig RJ, et al. Morphea: The 2023 update. Frontiers in Medicine. 2023;10. doi: 10.3389/fmed.2023.1108623.
8. Snarskaya ES, Vasileva KD. Localized scleroderma: actual insights and new biomarkers. International Journal of Dermatology. 2021;61(6):667–674. doi: 10.1111/ijd.15811.
9. Tang JC, Zheng WY, Han GM, Liu Sfei, Yang B. Successful Treatment of Paediatric Morphea with Tofacitinib. Acta Dermato-Venereologica. 2023;103. doi: 10.2340/actadv.v103.4805.
10. Wang Zhaojian, Ma Xuda, Xie Jiangmiao, Zou Kun, Long Xiao. Protocol for the Development of Chinese Guideline for the Diagnosis and Management of Localized Scleroderma. Medical Journal of Peking Union Medical College Hospital. 2024;15(6):1311–1317. doi: 10.12290/xhyxzz.2024-0656.

Publication:

«World of Medicine and Biology» Vol. 21 No. 93 (2025) , с. 18-22
УДК 616.5-004.1.

DOI:

https://doi.org/10.26724/2079-8334-2025-3-93-18-22